MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0026-895X/04/6503-665-674$20.00
Mol Pharmacol 65:665-674, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guo, J.
Right arrow Articles by Ikeda, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guo, J.
Right arrow Articles by Ikeda, S. R.

Endocannabinoids Modulate N-Type Calcium Channels and G-Protein-Coupled Inwardly Rectifying Potassium Channels via CB1 Cannabinoid Receptors Heterologously Expressed in Mammalian Neurons

Juan Guo, and Stephen R. Ikeda

Laboratory of Molecular Physiology, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland

Endocannabinoids may serve as retrograde messengers to inhibit neurotransmitter release during depolarization-induced suppression of inhibition (DSI) or excitation (DSE). We therefore tested whether endocannabinoids inhibit N-type voltage-dependent Ca2+ channels by activating Gi/o-protein-coupled CB1 cannabinoid receptors (CB1R)—a possible mechanism underlying DSI/DSE. Three putative endocannabinoids [2-arachidonylglycerol (2-AG), 2-arachidonyl glycerol ether (2-AGE), and anandamide (AEA)] and the cannabimimetic aminoalkylindole WIN 55,212-2 (WIN) inhibited whole-cell Ca2+ currents in rat sympathetic neurons previously injected with cDNA encoding a human CB1R. Agonist-mediated Ca2+ current inhibition was blocked by a selective CB1R antagonist [SR141716A, N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboximide hydrochloride] and pertussis toxin (PTX) pretreatment. The rank order of potency was WIN (IC50 = 2 nM) > 2-AGE (350 nM) ~ 2-AG (480 nM) > AEA (~3 µM), with each agonist displaying similar efficacy (approximately 50% maximal inhibition). Increasing CB1R expression level significantly enhanced AEA potency. AEA (10 µM) also inhibited Ca2+ channels in a voltage-independent, CB1R-independent, and PTX-insensitive manner, whereas 2-AG and 2-AGE were devoid of this activity. All three endocannabinoids activated G-protein-coupled inwardly rectifying potassium (GIRK) channels, GIRK1/4, heterologously expressed in sympathetic neurons. These results suggest a mechanism by which endocannibinoids might influence presynaptic function.


Received September 10, 2003; accepted November 18, 2003

Address correspondence to: Stephen R. Ikeda, M.D., Ph.D., Laboratory of Molecular Physiology, National Institute on Alcohol Abuse and Alcoholism, Park Building Room 150, 12420 Parklawn Drive MSC 8115, Bethesda, MD 20892-8815. E-mail: sikeda{at}mail.nih.gov




This article has been cited by other articles:


Home page
J. Immunol.Home page
P. W. Wacnik, K. M. Luhr, R. H. Hill, H.-G. Ljunggren, K. Kristensson, and M. Svensson
Cannabinoids Affect Dendritic Cell (DC) Potassium Channel Function and Modulate DC T Cell Stimulatory Capacity
J. Immunol., September 1, 2008; 181(5): 3057 - 3066.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
J. Guo, D. J. Williams, and S. R. Ikeda
N-Arachidonoyl L-Serine, a Putative Endocannabinoid, Alters the Activation of N-Type Ca2+ Channels in Sympathetic Neurons
J Neurophysiol, August 1, 2008; 100(2): 1147 - 1151.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
A. Sheinin, G. Talani, M. I. Davis, and D. M. Lovinger
Endocannabinoid- and mGluR5-Dependent Short-Term Synaptic Depression in an Isolated Neuron/Bouton Preparation From the Hippocampal CA1 Region
J Neurophysiol, August 1, 2008; 100(2): 1041 - 1052.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. Guo, D. J. Williams, H. L. Puhl III, and S. R. Ikeda
Inhibition of N-Type Calcium Channels by Activation of GPR35, an Orphan Receptor, Heterologously Expressed in Rat Sympathetic Neurons
J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 342 - 351.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
S. Oka, S. Arai, K. Waku, A. Tokumura, and T. Sugiura
Depolarization-induced Rapid Generation of 2-Arachidonoylglycerol, an Endogenous Cannabinoid Receptor Ligand, in Rat Brain Synaptosomes
J. Biochem., May 1, 2007; 141(5): 687 - 697.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
A. Neu, C. Foldy, and I. Soltesz
Postsynaptic origin of CB1-dependent tonic inhibition of GABA release at cholecystokinin-positive basket cell to pyramidal cell synapses in the CA1 region of the rat hippocampus
J. Physiol., January 1, 2007; 578(1): 233 - 247.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
P. Pacher, S. Batkai, and G. Kunos
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
H. H. Yin and D. M. Lovinger
Frequency-specific and D2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signaling
PNAS, May 23, 2006; 103(21): 8251 - 8256.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
P. J. Zhu and D. M. Lovinger
Retrograde Endocannabinoid Signaling in a Postsynaptic Neuron/Synaptic Bouton Preparation from Basolateral Amygdala
J. Neurosci., June 29, 2005; 25(26): 6199 - 6207.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics